Figure 7.

Acute effects of kisspeptin administration on markers of bone formation in humans. (A) Kisspeptin administration stimulated an acute increase in total osteocalcin levels compared to placebo, as depicted by absolute raw (*P = .013) and (B) percentage change from baseline (*P = .021, maximal increase 20.3% above placebo). (C) Kisspeptin administration stimulated an acute increase in carboxylated osteocalcin levels compared with placebo, as depicted by absolute raw (*P = .015) and (D) percentage change from baseline (*P = .014, maximal increase 24.3% above placebo). (E,F) Kisspeptin administration had no acute effect on circulating P1NP levels. Data shown as mean ± SEM, *P < .05, mixed-model analysis of variance, n = 26 healthy men.